Challenges
•
How will 1L immmune checkpoint inhibitors therapy affect
treatment selection in subsequent therapy lines?
•
What is the optimal/rationale cut off for PDL1 positivity?
•
What is the role of other investigational correlates, such as gene
expression profiles? Mutation burden?
•
Potential combinations
–
Anti–PD-(L)1 plus anti–CTLA-4
–
Immune checkpoint inhibitors plus CT, or other modalities such
as RT
–
Sequential approach
